

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Chimeric Therapeutics Limited (ASX: CHM)
ABN:	68 638 835 828

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Jennifer Chow
Date of Last Notice:	17 July 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Indirect																			
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Held via Broker nominee account																			
Date of change	14 December 2023																			
No. of securities held prior to change	<table><tr><td></td><td>Direct</td><td>Indirect</td><td>Total</td></tr><tr><td>Shares</td><td>1,811,609</td><td>7,639,315</td><td>9,450,924</td></tr><tr><td>Options</td><td>27,513,863</td><td>-</td><td>27,513,863</td></tr><tr><td>Performance rights</td><td>-</td><td>-</td><td>-</td></tr></table>					Direct	Indirect	Total	Shares	1,811,609	7,639,315	9,450,924	Options	27,513,863	-	27,513,863	Performance rights	-	-	-
	Direct	Indirect	Total																	
Shares	1,811,609	7,639,315	9,450,924																	
Options	27,513,863	-	27,513,863																	
Performance rights	-	-	-																	
Class	a) Fully Paid Ordinary Shares b) Unlisted Options c) Performance Rights																			
Number acquired	<table><tr><td></td><td>Direct</td><td>Indirect</td><td>Total</td></tr><tr><td>Shares</td><td>-</td><td>a) 8,643,603</td><td>8,643,603</td></tr><tr><td>Options</td><td>-</td><td>b) 15,139,467</td><td>15,139,467</td></tr><tr><td>Performance rights</td><td>-</td><td>c) 4,062,997</td><td>4,062,997</td></tr></table>					Direct	Indirect	Total	Shares	-	a) 8,643,603	8,643,603	Options	-	b) 15,139,467	15,139,467	Performance rights	-	c) 4,062,997	4,062,997
	Direct	Indirect	Total																	
Shares	-	a) 8,643,603	8,643,603																	
Options	-	b) 15,139,467	15,139,467																	
Performance rights	-	c) 4,062,997	4,062,997																	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed		Direct	Indirect	Total
	Shares	-	-	-
	Options	-	-	-
	Performance rights	-	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	a) \$0.035 per share. b & c) Non-cash, see 'nature of change' below.			
No. of securities held after change		Direct	Indirect	Total
	Shares	1,811,609	16,282,918	18,094,527
	Options	27,513,863	15,139,467	42,653,330
	Performance rights	-	4,062,997	4,062,997
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	a) Issue of shares as part of sign-on payment for forfeiture of long-term incentive payment from previous employer as per section 9.8 of Prospectus lodged 18 January 2021. b & c) Issue of options and performance rights as approved by Chimeric Therapeutics shareholders at the Annual General Meeting held on 14 November 2023.			

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A

+ See chapter 19 for defined terms.

If prior written clearance was provided, on what date was this provided?	N/A
--	-----

+ See chapter 19 for defined terms.